No Improvement in Treatment Success with Teriparatide Use for Hip and Pelvic Bone Fractures .
Effects of Teriparatide on Treatment Outcomes in Osteoporotic Hip and Pelvic Bone Fractures: Meta-analysis and Systematic Review of Randomized Controlled Trials.
Hip Pelvis. 2020 Dec; 32(4): 182–191.A total of 5 randomized controlled trials containing a total of 386 patients were included in this meta-analysis comparing teriparatide (n=181) and placebo (n=205) for the treatment of osteoporotic hip and pelvic bone fractures. The primary outcome of interest was the pooled incidence of treatment failure. Mean follow up of the included studies ranged from 3 to 19.5 months. Results of the meta-analysis revealed no statistically significant difference in the pooled rate of treatment failure between the teriparatide and placebo groups (OR=0.81 [95% CI 0.42, 1.53], p=0.16).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
